Autopsy report · NCT01663766

Phase I Study of Milatuzumab for Graft Versus Host Disease

“PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD no further patients would be enrolled”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 4 months before it started.
• Ran for about 1 year 3 months before it stopped.
• 12 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Gilead Sciences

Sponsor type

Industry

Conditions

GVHD (Acute or Chronic); Acute Myeloid or Lymphoblastic Leukemia (AML or ALL); Myelodysplastic Syndrome; Chronic Myelogenous Leukemia (CML); Multiple Myeloma (MM); Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)

Interventions

milatuzumab

Participants

12

Sites

1

Countries

United States

Trials that died the same way

• A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)
  “This was an inpatient study, but PI left inpatient service at MGH” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.